R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma (FIL_POLARDHAP)

December 6, 2023 updated by: Fondazione Italiana Linfomi - ETS

Phase II Randomized Clinical Trial to Evaluate the Efficacy of the Addition of Polatuzumab Vedotin to Standard Chemotherapy R-DHAP (POLA-R-DHAP) as Induction Pre-transplantation Therapy in Patients With Diffuse Large B-Cell Lymphoma Refractory/Relapsed After First Line Treatment.

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment plus autologous transplant.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment.

PET-CT scan performed after induction be centrally review for disease response. Responding patients (CR) after induction will be addressed to receive Autologous Stem Cells Transplantation (ASCT) consolidation as per local guidelines. Patients achieving PR can proceed with ASCT or with a 3rd-line treatment, according to the physician judgment. Patients in SD/PD will be diverted to salvage strategies.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Alessandria, Italy
        • A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia
        • Contact:
        • Principal Investigator:
          • Manuela Zanni, MD
      • Ancona, Italy
      • Avellino, Italy
        • Azienda Ospedaliera S.Giuseppe Moscati, S.C. Ematologia e Trapianto emopoietico
        • Contact:
        • Principal Investigator:
          • Sonya De Lorenzo, MD
      • Aviano, Italy
        • IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuto-correlati
        • Contact:
        • Principal Investigator:
          • Michele Spina, MD
      • Bari, Italy
        • IRCCS Istituto Tumori Giovanni Paolo II, U.O.C Ematologia
        • Contact:
        • Principal Investigator:
          • Giacomo Loseto, MD
      • Bergamo, Italy
        • Cliniche Humanitas Gavazzeni, Oncologia
        • Contact:
        • Principal Investigator:
          • Daniele Laszlo, MD
      • Brescia, Italy
      • Candiolo, Italy
        • Fondazione del Piemonte per l'Oncologia - IRCCS, Ematologia
        • Contact:
        • Principal Investigator:
          • Pio Manlio Mirko Frascione, MD
      • Catania, Italy
        • Arnas Nuovo Ospedale Garibaldi Nesima, U.O.C. Ematologia
        • Contact:
        • Principal Investigator:
          • Ugo Consoli, MD
      • Cuneo, Italy
        • A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo
        • Contact:
        • Principal Investigator:
          • Claudia Castellino, MD
      • Firenze, Italy
        • Azienda Ospedaliera Universitaria Careggi, Unitа funzionale di Ematologia
        • Principal Investigator:
          • Luca Nassi, MD
        • Contact:
      • Lecce, Italy
        • Ospedale Vito Fazzi, Ematologia
        • Contact:
        • Principal Investigator:
          • Valentina Bozzoli, MD
      • Legnano, Italy
        • ASST Ovest Milanese - Legnano, U.O.C. Ematologia
        • Contact:
        • Principal Investigator:
          • Michela Draisci, MD
      • Milano, Italy
        • ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia
        • Principal Investigator:
          • Emanuele Ravano, MD
        • Contact:
      • Milano, Italy
        • Istituto Scientifico San Raffaele, Unitа Linfomi - Dipartimento Oncoematologia
        • Contact:
        • Principal Investigator:
          • Andrés Ferreri, MD
      • Milano, Italy
        • Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda, Ematologia
        • Contact:
        • Principal Investigator:
          • Francesca Gaia Rossi, MD
      • Monza, Italy
        • Fondazione IRCCS San Gerardo dei Tintori, Ematologia
        • Contact:
        • Principal Investigator:
          • Federica Cocito, MD
      • Novara, Italy
        • AOU Maggiore della Caritа di Novara, SCDU Ematologia
        • Contact:
        • Principal Investigator:
          • Riccardo Bruna, MD
      • Palermo, Italy
        • A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia
        • Contact:
        • Principal Investigator:
          • Caterina Patti, MD
      • Perugia, Italy
      • Pescara, Italy
        • P.O. Spirito Santo di Pescara, UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi
        • Principal Investigator:
          • Elsa Pennese, MD
        • Contact:
      • Piacenza, Italy
        • Ospedale Guglielmo da Saliceto, U.O.Ematologia
        • Contact:
        • Principal Investigator:
          • Annalisa Arcari, MD
      • Pisa, Italy
      • Potenza, Italy
        • A.O.R. "San Carlo", U.O. Ematologia
        • Principal Investigator:
          • Michele Cimminiello, MD
        • Contact:
      • Ravenna, Italy
        • Ospedale delle Croci, Ematologia
        • Contact:
        • Principal Investigator:
          • Monica Tani, MD
      • Reggio Emilia, Italy
        • Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia
        • Contact:
        • Principal Investigator:
          • Maria Elena Nizzoli, MD
      • Roma, Italy
        • AO San Giovanni Addolorata, S.C. Ematologia
        • Contact:
        • Principal Investigator:
          • Erica Finolezzi, MD
      • Roma, Italy
      • Roma, Italy
        • Policlinico Umberto I - Universitа "La Sapienza", Istituto Ematologia -Dipartimento di Medicina Traslazionale e di Precisione
        • Contact:
        • Principal Investigator:
          • Alice Di Rocco, MD
      • Roma, Italy
        • Policlinico Universitario Campus Bio-Medico, Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare
        • Principal Investigator:
          • Luigi Rigacci, MD
        • Contact:
      • Rozzano, Italy
        • Istituto Clinico Humanitas, U.O. Ematologia
        • Contact:
        • Principal Investigator:
          • Monica Balzarotti, MD
      • Siena, Italy
        • AOU Senese, U.O.C. Ematologia
        • Contact:
        • Principal Investigator:
          • Alberto Fabbri, MD
      • Torino, Italy
        • A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria
        • Contact:
        • Principal Investigator:
          • Federica Cavallo, MD
      • Torino, Italy
        • A.O.U. Citta della Salute e della Scienza di Torino, S.C.Ematologia
        • Contact:
        • Principal Investigator:
          • Mattia Novo, MD
      • Treviso, Italy
      • Tricase, Italy
      • Trieste, Italy
        • Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), SC Ematologia
        • Contact:
        • Principal Investigator:
          • Francesco Zaja, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Histologically documented diagnosis of Diffuse Large B-Cell Lymphoma Not otherwise specified (DLBCL-NOS) as defined in the 2022 edition of the World Health Organization (WHO) classification; are also admitted documented diagnosis of:

    • T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
    • Epstein-barr virus (EBV)-associated DLBCL
    • Double-hit and triple-hit high grade B-cell lymphomas (HGBL DH/TH)
    • High-grade B-cell lymphoma, NOS (HGBL)
    • Transformed FL not previously untreated
    • Follicular large B-cell lymphoma (FLBL, former follicular 3b)
  2. Known availability of biopsy material (at relapse/refractory or previous most recent). Re-biopsy highly encouraged even if not mandatory. Central pathology review required, but not mandatory for registration and treatment start;
  3. Relapse or refractoriness after the first line R-chemo (R-CHOP o similar). Previous treatment with polatuzumab containing regimen is allowed as per clinician judgment;
  4. CAR-T not indicated or unavailable;
  5. Age 18-70 years. sGA mandatory for patients 65-70 years old: only category FIT admitted [20] (see Appendix A);
  6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 if not related to lymphoma disease (see Appendix B);
  7. Measurable disease ≥ 1.5 cm in longest diameter, and measurable in 2 perpendicular dimensions;
  8. Normal blood count defined as: neutrophils at least 1.500/mmc, platelets at least 75.000/mmc, haemoglobin at least 8,0 g/dL with transfusion independence, unless abnormalities due to underlying disease (bone marrow involvement), at the moment of signing informed consent;
  9. Adequate liver function, assessed by baseline laboratory values; the increase to up to 2.5 ULN for transaminases and up to 1.5 ULN for bilirubin admitted for cases with documented liver involvement by lymphoma;
  10. Adequate renal function defined as creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula; see Appendix C)
  11. Subjects HBsAg negative but positive for antibodies to hepatitis B core antigen with undetectable HBV-DNA measured by real-time polymerase chain reaction (PCR).
  12. Women of childbearing potential (WOCBP) and men must agree to use effective contraception if sexually active. Females of childbearing potential and males with female partners of reproductive potential should be advised to use effective contraception while receiving polatuzumab vedotin and for 9 months after the last dose of polatuzumab vedotin for female patients and for 6 months after the last dose of polatuzumab vedotin for male patients with female partners of reproductive potential. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control method (failure rate of less than 1%) e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner. The use of condoms by male patients is required (even if surgically sterilized, i.e., status post vasectomy) unless the female partner is permanently sterile. Full sexual abstinence is admitted when this is in line with the preferred and usual lifestyle of the subject, for the same time period planned for other methods of birth control (see above). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods for the female partner) and withdrawal are not acceptable methods of contraception
  13. WOCBP must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study;
  14. Life expectancy > 6 months;
  15. Subject understands and voluntarily signs an informed consent form approved by the National Ethics Committee prior to the initiation of any screening or study-specific procedures;
  16. Subject must be able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Any histology other than DLBCL
  2. Primary mediastinal lymphoma (PMBCL)
  3. Known central nervous system lymphoma
  4. Known history of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies
  5. Contraindication to any drug in the chemotherapy regimen
  6. Left ventricular ejection fraction (LVEF) < 50%
  7. Neuropathy ≥ grade 2

  8. Subject is:

    • Seropositive for hepatitis B, defined by a positive test for hepatitis B surface antigen [HBsAg]. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (HBsAb positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR
    • Known to be seropositive for hepatitis C. EXCEPTION: Patients with presence of HCV antibody, but PCR negative for HCV-RNA are eligible
    • Positive for human immunodeficiency virus (HIV) infection
  9. Any uncontrolled active systemic infection requiring intravenous (IV) antibiotics
  10. History of stroke or intracranial hemorrhage within the past 6 months.
  11. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
  12. Clinically significant cardiovascular disease
  13. Major surgical intervention prior 4 weeks to enrollment if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment
  14. Prior malignancies other than lymphoma in the last 5 years with exception of currently treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix
  15. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety
  16. If female, the patient is pregnant or breast-feeding
  17. Patients participating in other clinical studies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: R-DHAP
R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
Drug: R-DHAP
  • Rituximab 375 mg/m2 IV on D0 or D1
  • Dexamethasone 40 mg/day IV or PO on D1-4
  • Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3
  • Cisplatin 100 mg/ m2 IV on D1
Experimental: Pola-R-DHAP
Pola-R-DHAP x4 + autologous transplant/salvage treatment (based on centrally review response)
Drug: Pola-R-DHAP
  • Polatuzumab Vedotin 1.8 mg/kg IV on D1
  • Rituximab 375 mg/m2 IV on D0 or D1
  • Dexamethasone 40 mg/day IV or PO on D1-4
  • Ara-C 2 g/m2 IV on D2 (2 doses every 12h) or D2 and D3
  • Cisplatin 100 mg/ m2 IV on D1

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression free survival (PFS)
Time Frame: From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Time between the randomization to first documentation of recurrence, progression or death from any cause
From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Event-Free Survival (EFS)
Time Frame: From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Time between the randomization to any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g., disease progression, toxicity, patient preference, initiation of a new treatment without documented progression) or death from any cause.
From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Complete response rate (CRR)
Time Frame: From treatment start up to end of treatment evaluation (about 6 months)
CRR will be defined according to Response Criteria for NHL with PET (Lugano 2014). CRR will include only patients who achieved a CR and will be evaluated on assessed patients and on all treated patients, considering patients without a response assessment (due to any reason) as non-responders.
From treatment start up to end of treatment evaluation (about 6 months)
Overall response rate (ORR)
Time Frame: From treatment start up to end of treatment evaluation (about 6 months)
ORR will be defined as the proportion of patients who have a partial or complete response to therapy (CR+PR).
From treatment start up to end of treatment evaluation (about 6 months)
Overall Survival (OS)
Time Frame: From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Time between randomization to death from any cause.
From treatment start up to 30 months (6 months treatment period and 24 months of follow-up)
Incidence and severity of AEs
Time Frame: From start to end of induction treatment evaluation (about 3 months)
Incidence and severity of AEs in R-DHAP vs POLA-R-DHAP according to latest CTCAE criteria during induction immunochemotherapy
From start to end of induction treatment evaluation (about 3 months)
Adequate stem cells mobilization
Time Frame: From beginning of 2nd cycle to end of induction treatment evaluation (about 2 months)
Adequate stem cells mobilization will be defined by the target cell harvesting of 3 x 10^6 CD34+ cells/kg
From beginning of 2nd cycle to end of induction treatment evaluation (about 2 months)
Autologous consolidation feasibility
Time Frame: At time of end of treatment assessment (up to 6 months from treatment begin)
Proportion of patients receiving autologous consolidation after POLA-R-DHAP vs R-DHAP
At time of end of treatment assessment (up to 6 months from treatment begin)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fondazione Italiana Linfomi - ETS

Collaborators

Roche Pharma AG

Investigators

  • Principal Investigator: Monica Balzarotti, MD, Dipartimento di Oncologia Medica ed Ematologia - Istituto Clinico Humanitas - Rozzano (MI)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2024

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

July 21, 2023

First Submitted That Met QC Criteria

July 21, 2023

First Posted (Actual)

July 28, 2023

Study Record Updates

Last Update Posted (Estimated)

December 7, 2023

Last Update Submitted That Met QC Criteria

December 6, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FIL_POLA-R-DHAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diffuse Large B-cell Lymphoma Recurrent

Clinical Trials on R-DHAP

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe